1 |
Aberle SW, Kletzmayr J, Watschinger B, et al (2001). Comparison of sequence analysis and the inno-lipa hbv dr line probe assay for detection of lamivudine-resistant hepatitis b virus strains in patients under various clinical conditions. J Clin Microbiol, 39, 1972-4.
DOI
ScienceOn
|
2 |
Aghasadeghi MR, Bahramali G, Sadat SM, et al (2011). Detection of hepatitis b virus variants in hbv monoinfected and hbv/hiv coinfected iranian patients under lamivudine treatment. Curr HIV Res, 9, 263-9.
DOI
|
3 |
Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM (2008). Hepatitis B virus genotype and ymdd motif mutation profile among patients infected with hbv and untreated with lamivudine. Int J Infectious Diseases, 12, 83-7.
DOI
|
4 |
Arslan U, Ural O, Findik D (2008). YMDD motif variants detected by inno-lipa hbv assay in chronic hepatitis b patients during lamivudine therapy. Mikrobiyol Bul, 42, 445-50.
|
5 |
Brunelle MN, Jacquard AC, Pichoud C, et al (2005). Susceptibility to antivirals of a human hbv strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 41, 1391-8.
DOI
ScienceOn
|
6 |
Buti M, Elefsiniotis I, Esteban R (2007). Adefovir for lamivudine resistant hbv: More than meets the eye - reply. J Hepatology, 47, 619-20.
DOI
|
7 |
Chen CH, Lee CM, Tung WC, et al (2010). Evolution of fulllength hbv sequences in chronic hepatitis b patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatology, 52, 478-85.
DOI
ScienceOn
|
8 |
Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS (2009). Sensitivity and accuracy of an updated line probe assay (hbv dr v.3) in detecting mutations associated with hepatitis b antiviral resistance. J Hepatology, 50, 42-8.
DOI
|
9 |
Elefsiniotis IS, Paparizos V, Dourakis SP, et al (2005). Clinical outcome of long-term lamivudine treated chronic hbv infected and hiv/hbv coinfected patients. J Clinical Virology, 33, 80-2.
DOI
|
10 |
Fallahian F, Alavian S, Kayvani H, Alaeddini F, Zamani F (2010). Lamivudine resistance in iranian chronic hepatitis b patients. Shiraz E-Medical J, 11, 63-73.
|
11 |
Fasano M, Lampertico P, Marzano A, et al (2012). HBV DNA suppression and hbsag clearance in hbeag negative chronic hepatitis b patients on lamivudine therapy for over years. J Hepatol, 56, 1254-8.
DOI
ScienceOn
|
12 |
Geng H, Hua B, Wang H, et al (2006). Dual-probe assay for detection of lamivudine-resistance hepatitis b virus by realtime pcr. J Virological Methods, 132, 25-31.
DOI
|
13 |
Kamar N, Sandres-Saune K, Ribes D, et al (2004). Effects of long-term lamivudine therapy in renal-transplant patients. J Clinical Virology, 31, 298-303.
DOI
|
14 |
Li ZG, Chen LY, Huang J, et al (2005). Quantification of the relative levels of wild-type and lamivudine-resistant mutant virus in serum of hbv-infected patients using microarray. J Viral Hepat, 12, 168-75.
DOI
|
15 |
Liu H, Mao R, Fan L, et al ( 2011). Detection of lamivudine- or adefovir-resistant hepatitis b virus mutations by a liquid array. J Virological Methods, 175, 1-6.
DOI
|
16 |
Liu YC, Zhang WL, Hu Y, et al (2010). Detection of hbv resistant mutations related to lamivudine, adefovir and entecavir by reverse hybridization technique. Cma J, 18, 414-8.
|
17 |
Moosavy SH, Froutan H, Andrabi Y, et al (2011). Frequency of ymdd mutations in patients with chronic hepatitis b untreated with antiviral medicines. Med J Islamic Republic of Iran, 25, 186-93.
|
18 |
Voirin E, Behr JP, Kotera M (2007). Versatile synthesis of oligodeoxyribonucleotide oligospermine conjugates. Nature Protocols, 2, 1360-8.
DOI
|
19 |
Noir RG, Kotera M, Pons B, Remy JS, Behr JP (2008). Oligonucleotide-oligospermine conjugates (zip nucleic acids): A convenient means of finely tuning hybridization temperatures. J Am Chem Soc, 9, 13500-5.
|
20 |
Rizzetto M, Tassopoulos NC, Goldin RD, et al (2005). Extended lamivudine treatment in patients with hbeag-negative chronic hepatitis b. J Hepatology, 42, 173-9.
|
21 |
Wu F, Wu MJ, Zhuge XL, Zhu SM, Zhu B ( 2012). Correlation of the occurrence of YMDD mutations with hbv genotypes, hbv-DNA levels, and hbeag status in chinese patients with chronic hepatitis b during lamivudine treatment. Pancreatic Diseases Int, 11, 172-6.
DOI
|
22 |
Zhou YB, Wang YF, Zhang Y, et al (2012). In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis b virus isolates. Eur J Pharmacol, 683, 10-5.
DOI
|